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Abstract
Objectives: Impaired vascular pathophysiology and increased cardiovascular (CV) mortality are associated with
rheumatoid arthritis (RA). To date, no genomic analysis of RA- and RA treatment-related vascular pathophysiology
has been published. In this pilot study, we performed gene expression profiling in association with vascular
pathophysiology in RA patients.
Methods: Sixteen and 19 biologic-naïve RA patients were included in study 1 and study 2, respectively. In
study 1, genetic signatures determined by microarray were related to flow-mediated vasodilation (FMD),
pulse-wave velocity (PWV), and common carotid intima-media thickness (IMT) of patients. In study 2, clinical
response (cR) vs non-response (cNR) to 1-year etanercept (ETN) or certolizumab pegol (CZP) treatment, as well
as “vascular” response (vR) vs non-response (vNR) to biologics, were also associated with genomic profiles.
Multiple testing could not be performed due to the relatively small number of patients; therefore, our pilot
study may lack power.
Results: In study 1, multiple genes were up- or downregulated in patients with abnormal vs normal FMD,
IMT, and PWV. In study 2, there were 13 cR and 6 cNR anti-tumor necrosis factor (TNF)-treated patients. In
addition, 10, 9, and 8 patients were FMD-20%, IMT-20%, and PWV-20% responders. Again, vascular responder
status was associated with changes of the expression of various genes. The highest number of genes showing significant
enrichment were involved in positive regulation of immune effector process, regulation of glucose transport, and Golgi
vesicle budding.
Conclusion: Differential expression of multiple genetic profiles may be associated with vascular pathophysiology
associated with RA. Moreover, distinct genetic signatures may also be associated with clinical and vascular
responses to 1-year anti-TNF treatment.
Keywords: Rheumatoid arthritis, Etanercept, Certolizumab pegol, Gene expression, Genetic signature, Atherosclerosis,
Vascular pathology, Prediction, Response
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Key messages
– Rheumatoid arthritis is associated with impaired
vascular pathophysiology
– Endothelial dysfunction and atherosclerosis may be
associated with altered genetic signature
– Anti-TNF therapy may improve vascular function
associated by changes in gene expression
Introduction
Accelerated atherosclerosis and increased cardiovascular
(CV) morbidity and mortality have been associated with
rheumatoid arthritis (RA). Vascular pathophysiology
found in RA has been characterized by endothelial dys-
function, increasing arterial stiffness and overt atheroscler-
osis. These alterations are indicated by impaired brachial
artery flow-mediated vasodilation (FMD), arterial
pulse-wave velocity (PWV), and carotid plaque plus ca-
rotid intima-media thickness (IMT), respectively [1–4].
Several other non-invasive techniques have been available
to detect vascular pathophysiology [1]. All these changes
can be preclinically detected in RA with a negative history
of CV disease (CVD) [2–6].
Targeted therapies including tumor necrosis factor α
(TNF-α) inhibitors are highly effective in RA [7, 8]. The
efficacy of these biologics may differ from patient to pa-
tient. Therefore, there is a high need for the identification
of biomarkers including genetic signatures that may pre-
dict therapeutic response (R) vs non-response (NR) to bio-
logics [9–12]. Indeed, gene expression profiling has been
successfully used on tissue samples or blood for the identi-
fication of biomarkers and/or genome classifiers in various
diseases [13, 14]. As described by several investigators,
gene expression patterns of peripheral blood mononuclear
cells (PBMCs) may be associated with response to therap-
ies or disease progression [9–12, 15]. We have also per-
formed gene expression studies and identified certain
genomic signatures that may be associated with responses
to infliximab [16] and tocilizumab [17]. Thus, we devel-
oped a standard protocol that could utilize genomics as
biomarkers of disease or therapeutic outcomes [16, 17].
Both RA and atherosclerosis have strong genetic back-
grounds. In RA, genome-wide association studies (GWAS)
revealed numerous susceptibility alleles including
HLADRB1, PTPN22, TRAF1/C5, STAT4, PADI4, IRF5,
FCGR, IL2RA, IL2RB, CD40, CCR6, and CCL21.More than
40 single nucleotide polymorphisms (SNPs) have been asso-
ciated with RA [18]. In atherosclerosis, a GWAS study car-
ried out on more than 100,000 Europeans revealed
association of more than 30 genes with coronary athero-
sclerosis. These included matrix molecule (e.g., ADAMTS7,
ANKS1A, COL4A1), lipid (e.g., LPA, LDLR), chemokine
(e.g., CXCL12), and other genetic loci [19]. The roles of
other “lipid-related genes” including ABCA1, APOA5,
LCAT, CETP, and SORT1, as well as more than 50 “non-li-
pid” genes, have also been identified in atherosclerosis by
GWAS [20]. HLADRB1 has been associated with both RA
[18] and CVD [19].
It is also possible that RA and the associated CVD may
have common genetic denominators. In this respect,
mostly single-allele studies have been performed. Farra-
gher et al. [21] reported that certain HLA-DRB1 alleles,
mainly those functioning as shared epitope (SE), are asso-
ciated with increased CV mortality in RA. For example, in
comparison to RA patients carrying no or one SE allele,
those with HLA-DRB1*01/*04 exert a three times higher
risk for CV death [21]. Gonzalez-Gay et al. [22] also con-
firmed a relationship between SE alleles and CV morbidity
and mortality. Studies on single non-HLA alleles were pri-
marily performed by Gonzalez-Gay et al. [23, 24]. For ex-
ample, the A1298C SNP in the MTHFR gene was
associated with occurrence of CV events in RA patients.
A SNP in the SMAD3 gene increased the risk for cerebro-
vascular accident in ACPA-negative RA patients. The
HLA-DR1*04/*04 genotype and an SNP in the CD40 gene
were associated with endothelial dysfunction and IMT, re-
spectively. SNPs in the IRF5 and osteoprotegerin (OPG)
genes could also be associated with vascular pathology.
On the other hand, no associations between atheroscler-
osis/CVD or SNPs in the IFNG, JAK3, PON1, ADAMTS7,
CARD8, CXCL12, ADIPOQ, and TLR4 alleles could be
demonstrated [23, 24]. Yet, association of RA and athero-
sclerosis with complex genetic signatures has not yet been
elucidated.
Therefore, we wished to determine associations between
clinical responses to biologics, vascular pathophysiology,
and gene expression patterns in a pilot study. Here, we per-
formed global gene expression profiling in PBMCs of RA
patients. We associated gene expression profiles (signa-
tures) with (1) normal vs abnormal FMD, PWV, and IMT
status of patients (study 1), (2) clinical response (cR) vs
non-response (cNR) to 1-year biologic (etanercept, ETN, or
certolizumab pegol, CZP) treatment as defined by EULAR
response criteria (study 2), and (3) “vascular” response (vR)
vs non-response (vNR) as defined by sufficient changes in




In study 1, 16 Caucasian, biologic-naive RA patients (15 fe-
males, 1 male), with a mean age of 53.7 ± 5.7 (range 42–60)
years and a mean disease duration of 10.0 ± 10.2 (range 2–
44), were included. In study 2, 19 biologic-naïve RA patients
(18 females, 1 male; mean age 54.3 ± 4.8 [range 43–60] years,
12.1 ± 10.9 [range 2–44] years) were recruited. Later, 12 pa-
tients received ETN, and 7 CZP. All RA patients met the
2010 EULAR/ACR classification criteria for RA [25].
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All blood samples were obtained after the subjects
fasted overnight for 12 h locally between 8:00 AM and
9:00 AM before the first admission of biologics. Medica-
tion remained unchanged during the study.
The inclusion criteria in both studies included con-
firmed diagnosis of RA, age between 20 and 60, failure to
respond to at least two DMARDs, active disease (DAS28
> 3.2), and anti-TNF therapy-naïve patients. Corticosteroid
therapy (prednisone ≤ 10mg per day) was allowed pro-
vided that the dosage had been stable for at least 2months
before entry. Also non-steroidal anti-inflammatory drugs
(NSAID) were allowed in doses stable for at least 1 month
before baseline. All patients received 10–25mg/week oral
methotrexate (MTX) treatment, which had been stable for
at least 4 weeks before baseline. Exclusion criteria in-
cluded pregnancy or breastfeeding, current or recent ma-
lignancies, active infectious disease, patients with a history
of arthritis or connective tissue disease other than RA,
and smoking.
Disease activity was assessed by determining the
28-joint Disease Activity Score (DAS28) at baseline and
then 12months after the initiation of anti-TNF treat-
ment in study 2.
Clinical responder (cR vs cNR) status was determined
after 12 months of treatment with either ETN or CZP by
the EULAR response criteria originally described by Van
Gestel et al. [26].
The Medical Research Council of Hungary gave ethical
approval for this study (No. 9732-2/2012/EHR). In
addition, the Institutional Review Board of the Univer-
sity of Debrecen Faculty of Medicine also approved the
protocol. The study was in compliance with the Helsinki
Declaration. Signed informed consent was obtained from
all individuals providing blood samples.
Assessment of vascular physiology by ultrasound
Brachial artery FMD was assessed as described before [2, 27,
28]. In brief, ultrasound examination was performed on the
right arm using a 10-MHz linear array transducer (ultra-
sound system: HP Sonos 5500) by a single trained sonogra-
pher after 30 min of resting in a temperature-controlled
room (basal value for FMD). A B-mode longitudinal section
was obtained of the brachial artery above the antecubital
fossa. In order to assess FMD, reactive hyperemia was in-
duced by release of a pneumatic cuff around the forearm in-
flated to suprasystolic pressure for 4.5min. After deflation,
the maximal flow velocity and the arterial diameter was con-
tinuously recorded for 90 s. Flow velocities, the baseline
diameter, and FMD were ECG gated and detected offline.
FMD values were expressed as % change from baseline
(resting) value (FMD%). In our previous work, we divided
RA patients into “high (normal) FMD” and “low (impaired)
FMD” subsets by defining a cutoff value of 5% [2]. We used
the same cutoff in the present studies.
The IMT measurements were carried out as described
before [2, 28, 29]. Briefly, a duplex ultrasound system
(HP Sonos 5500, 10MHz linear array transducer) was
used to assess the common carotid arteries by a single
observer. Longitudinal high-resolution B-mode ultra-
sound scans were employed over both the right and left
common carotid arteries and were R-synchronized and
recorded. The offline measurements were performed 1
cm proximal to the carotid bulb in the far wall. IMT was
defined as the distance between the first and second
echogenic lines from the lumen taking the average of 10
measurements on both sides. IMT values were expressed
in millimeters. In our previous work, we divided RA pa-
tients into “high (increased) IMT” and “low (normal)
IMT” subsets by using a cutoff value of 0.65 mm [2]. We
used the same cutoff in the present studies.
With respect to arterial stiffness, PWV was calculated
automatically by a TensioClinic arteriograph system (Ten-
siomed Ltd., Budapest, Hungary) with the quotient of the
distance between the jugular fossa and symphysis as de-
scribed before [28, 30, 31]. If an artery is elastic, PWV is low.
With decreased arterial elasticity, PWV rises. The arterio-
graph assesses this parameter from the oscillometric data
obtained from the 35mmHg suprasystolic pressure of the
brachial artery [30, 31]. In order to obtain reproducible re-
sults, the patient had to rest in a supine position for at least
10 min before the assessment in a quiet room. PWV is
expressed in meters per second. Based on our previous ex-
perience [28, 31], we used a cutoff value of 8m/s, where
PWV ≤ 8m/s and PWV >8m/s indicated “low (normal)”
and “high (increased)” PWV, respectively.
In study 2, we defined the arbitrary vascular responder
status (vR vs vNR). Patients achieving at least 20% im-
provement in FMD, IMT, or PWV were considered vas-
cular responders (vR). Patients achieving ≥ 20%
improvement in at least two out of the three vascular
parameters (FMD, IMT, PWV) were considered good
vascular responders (GVR).
PBMC and RNA isolation
Venous peripheral blood samples were collected (10ml)
in Venous Blood Vacuum Collection Tubes containing
EDTA (BD Vacutainer K2EDTA). PBMCs were separated
by Ficoll gradient centrifugation. Total RNA was extracted
from PBMCs using Trizol reagent (Invitrogen), according
to the manufacturer’s protocol. RNA quality was checked
on an Agilent Bioanalyzer 2100 (Agilent Technologies); all
samples had a 28S/18S ratio between 1.5 and 2.0, and the
RNA Integrity Number was between 9 and 10. Quantity
was determined by NanoDrop (Thermo Scientific).
Microarray analysis and statistics
Affymetrix GeneChip Human Primeview array was used
to analyze global expression pattern of 28,869
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well-annotated genes. 3’ IVT Expression Kit (Affymetrix)
and GeneChip WT Terminal Labeling and Control Kit
(Affymetrix) were used for amplifying and labeling 250
ng of RNA samples. Samples were hybridized at 45 °C
for 16 h, and then standard washing protocol was per-
formed using a GeneChip Fluidics Station 450 and the
arrays were scanned on a GeneChip Scanner 7G
(Affymetrix).
Microarray data were analyzed by Genespring GX12
software (Agilent Technologies). Affymetrix data files
were imported using the RMA algorithm and median
normalization was performed. To identify differentially
expressed genes between clinical conditions, statistical
analysis was performed using a Mann-Whitney U test; p
value < 0.05 was considered to significant difference. We
used hierarchical clustering and principal component
analysis (PCA) to show the separation of clinical condi-
tions by the differentially expressed genes. Microarray
data were submitted to Gene Expression Omnibus
(GEO), accession number: GSE126476.
Gene Ontology (GO) analysis was performed using
Cytoscape 3.4.0 software (cytoscape.org) with the
ClueGO application. The settings were the following:
GO biological process, GO immune system process, and
KEGG human diseases pathways; statistical options:
two-sided hypergeometric test and Benjamini-Hochberg
FDR for multiple testing correction. Significantly
enriched GO categories were considered to p value <
0.05 and κ score < 0.4.
The association between clinical and various vascular
responses was analyzed by Pearson’s correlation (p < 0.05).
Results
Gene expression profiles may differentiate patients with
normal vs impaired vascular pathophysiology
In study 1, among the 16 RA patients, 11 had low (< 5%; red
in Fig. 1a, d) and 5 had high (≥ 5%; blue) FMD values (Fig. 1a).
Similarly, low (≤ 0.65mm; red in Fig. 1b, e) and high (> 0.65
mm; blue) IMT values were observed in 11 and 5 patients, re-
spectively (Fig. 1b, e). PWV was low (≤ 8m/s; red in Fig. 1c, f)
in 9 and high (> 8m/s; blue) in 7 patients (Fig. 1c, f).
Two genes (CD74, ZNF718) were up- and 12 genes
were significantly downregulated in patients with im-
paired (low) FMD compared to those with normal (high)
FMD. The 12 downregulated genes are FOLR3, ADM,
HP, DSC2, ANXA3, LILRA5, PLSCR1, AKAP12, VNN2,
TCN1, HDC, and NFIL3 (Additional file 1: Table S1;
Fig. 1d).
Altogether 62 up- and 129 downregulated genes were
associated with increased (high) versus normal (low) IMT.
The upregulated genes included G0S2, NRGN, ITGA2B,
C3, FLNA, IRF5, ABCC3, CAPNS1, IL2RG, CCL4L1,
ACTN1, HLAB, HLAC, TNFAIP3, and MYO1G. Among
others, PPP1CB, HLADRB4, IFNGR1, LRRN3, CCR2,
CD46, IFI44L, IFIT1, TLR10, CD164, IFIT2, SMAD4, and
SGPP1 genes were downregulated (Additional file 1: Table
S1; Fig. 1e).
Fig. 1 Study 1. Differential gene expression associated with vascular pathophysiology in RA. The heatmaps indicate differential gene regulation in
patients with low (red) versus high (blue) FMD (a), IMT (b), and PWV (c). Among the 16 patients, 11 had impaired (low; red) and 5 normal (high;
blue) FMD (a). Eleven patients had normal (low; red) and 5 had increased (high; blue) IMT (b). Nine patients had normal (low; red) and 7 had
increased (high; blue) PWV (c). See Table S1 for the actual gene data
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Finally, 32 genes showed differential expression between
patients with increased (high) compared to normal (low)
PWV. The changes were slight in most of these genes,
and only two genes showed ≥ 2-fold change difference be-
tween the high vs. low comparison, HLAB/HLAC (upregu-
lated) and LRRN3 (downregulated) (Additional file 1:
Table S1; Fig. 1f).
Association between clinical and vascular response upon
1-year anti-TNF therapy
In study 2, 19 biologic-naïve RA patients were treated
with either ETN or CZP for 12 months. Clinical (cR vs
cNR) and vascular (vR vs vNR) responder status was
assessed after 1 year as described above. There were 13
cR and 6 cNR patients (Table 1; Fig. 2; cR: blue, cNR:
red). According to the arbitrary definition of vascular re-
sponder status described above, 10 patients were
FMD-20% responders (Table 1; Fig. 3a), 9 were
IMT-20% responders (Table 1; Fig. 3b), and 8 were
PWV-20% responders (Table 1; Fig. 3c). Altogether, 8
patients achieved the GVR-20% status (Table 1; Fig. 3d)
(in the figures, responders are in blue and
non-responders are in red). Out of the 19 patients, 5 pa-
tients achieved response in all three vascular parameters
(FMD, IMT, PWV), and 3 in two parameters.
Clinical and vascular responder status of the treated
patients was also compared (Table 2). When clinical re-
sponder status was correlated with FMD, IMT, or PWV
responder status, as well as the GVR status, IMT re-
sponse showed a tendency of correlation with the clin-
ical response (R = 0.418, p = 0.075) (Table 2). Yet, 8
FMD, 8 IMT, 6 PWV vRs, and 7 patients achieving GVR
status were also cRs. On the other hand, 4, 5, 4, and 5
patients were both FMD, IMT, PWV, and global vascular
NRs and cNRs, respectively (Table 2).
Differential baseline gene expression between clinical and
vascular responders vs non-responders
First, baseline gene expression was associated with cR vs
cNR status after 12 months of anti-TNF therapy (Fig. 2;
Additional file 2: Table S2). Only 5 genes (HLADRB4,
TMEM176A, TMEM176B, IFI44, and PLSCR1) were sig-
nificantly (≥ 2-fold) upregulated in cR vs cNR patients
(p < 0.05). No significantly downregulated genes were
found (Fig. 2; Additional file 2: Table S2).
Regarding vascular responses (vR) to biologics, the asso-
ciations of baseline genetic signatures with vR vs vNR after
1-year ETN or CZP therapy were determined with respect
to FMD, IMT, PWV, and GVR. FMD-20% vR (≥ 20% im-
provement/increase in FMD after 12months) vs vNR was
Table 1 Clinical and vascular responder status in ETN- or CZP-treated RA patients (n = 19) (study 2)
Subject Biologic Clinical response FMD response IMT response PWV response Good vascular response
1 ETN R R R R R
2 ETN R NR R NR NR
3 CZP R R R NR R
4 ETN R NR NR NR NR
5 ETN R R NR NR NR
6 ETN R R NR R R
7 CZP R NR R NR NR
8 ETN R R R R R
9 CZP R R R R R
10 ETN R NR R R R
11 ETN R NR NR NR NR
12 ETN R R R R R
13 ETN R R NR NR NR
14 CZP NR R NR NR NR
15 ETN NR NR NR NR NR
16 CZP NR NR NR NR NR
17 CZP NR NR NR R NR
18 CZP NR NR NR NR NR
19 ETN NR R R R R
R (n) 13 10 9 8 8
NR (n) 6 9 10 11 11
R responder, NR non-responder, ETN etanercept, CZP certolizumab pegol
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associated with significant (≥ 2-fold) upregulation of a sin-
gle gene (NEFL) and downregulation of two genes (JUN
and GYPB) (p < 0.05) (Fig. 3a; Additional file 2: Table S2).
IMT-20% vR (≥ 20% improvement/decrease in IMT after
12months) vs vNR was associated with upregulation of 18
(e.g., various immunoglobulin and HLA genes,TNFRSF17,
CD74, FCRL5, CD79A, IFITM3) and downregulation of
12 genes (e.g., CXCL5, ITGB3, NEFL) (Fig. 3b, Add-
itional file 2: Table S2). PWV-20% vR (≥ 20% improve-
ment/decrease in PWV after 12months) vs vNR was
associated with upregulation of three genes (IFNG, JUN,
and CCL4L1/L2) and downregulation of five genes
(HLAC, GNB4, NRG1, NEFL, and FKBP5) (Fig. 3c, Add-
itional file 2: Table S2). Finally, a good vascular response
(GVR-20%) was defined as improvement by ≥ 20% in at
least two vascular parameters (increase in FMD, decrease
in IMT or PWV). In this respect, GVR-20% vR vs vNR
was associated with the upregulation of 11 genes (e.g.,
various immunoglobulin genes, SCN3A, CD79A, and
FCRL5) and downregulation of two genes (NEFL and
CES1/CES1P1) (Fig. 3d, Additional file 2: Table S2).
Clustering and network analysis of differentially
expressed genes
Gene Ontology (GO) analysis was performed in order to
demonstrate functional categories of differentially expressed
genes, which showed at least twofold change up- or down-
regulation in study 2. As IMT has been associated with
differential expression of numerous genes, we performed
GO on IMT-, but not on FMD- or PWV-associated genes.
Figure 4 shows the overrepresented functional categories of
differentially expressed IMT-associated genes. The highest
Fig. 2 Study 2. Differential gene expression associated with clinical response or non-response after 12 months of anti-TNF therapy. Altogether, 13
patients were responders and 6 were non-responders. Heatmap indicates differential gene regulation in clinical responders (blue) vs non-responders (red)
Table 2 Association of clinical and vascular responses in ETN- or CZP-treated RA patients (n=19) (Study 2)*
FMD response IMT response PWV response Good Vascular 
response
R NR R NR R NR R NR
Clinical 
Response
R 8 5 8 5 6 7 7 6
NR 2 4 1 5 2 4 1 5
*Grey cells indicate R-R and NR-NR associations in clinical vs vascular responses
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number of genes showing significant enrichment was in-
volved in positive regulation of immune effector process,
regulation of glucose transport, Golgi vesicle budding, and
others (Fig. 4).
Discussion
Accelerated atherosclerosis, as well as increased CV mor-
bidity and mortality, has been associated with RA [2, 4,
32, 33]. Several HLA and non-HLA genes have been im-
plicated in susceptibility to RA [18, 34, 35] and athero-
sclerosis [19, 22, 36]. There may be common genetic
factors underlying both RA and atherosclerosis [21, 23,
24]. Previous genetic studies mostly revealed the involve-
ment of single SNPs in the background of RA-driven ath-
erosclerosis. Thus, both HLA-DRB1 [21, 22, 37] and
non-HLA alleles [23, 24] have been detected in this re-
spect. To our knowledge, no complex genomic studies
have been performed and published in association with
CV pathophysiology or the effect of anti-TNF therapy on
vascular function in RA. Therefore, we conducted a pilot
study on a group of RA patients and compared clinical
data, vascular pathophysiology, and patterns of differen-
tially expressed genes.
Some genes were differentially regulated in association
with FMD, IMT, and PWV or in conjunction to clinical
and vascular responses to anti-TNF treatment. As dis-
cussed above, the Spanish group described numerous
SNPs associated with RA-related CV disease [23, 24].
The genes identified by them, similarly to our study,
encoded HLA, pro-inflammatory cytokines, and several
other molecules related to autoimmunity and inflamma-
tion. As no complex genomic study or genetic study on
biologic-treated patients have been conducted, our re-
sults cannot be compared to any previous studies.
In study 1, we applied pre-determined cutoff values for
FMD, IMT, and PWV in order to define and to compare
abnormal and normal vascular functions in 16 RA patients.
A ≥ 2-fold change in gene expression was considered mean-
ingful and significant. Some genes were differentially
expressed in RA patients with abnormal (high) vs normal
(low) IMT. Much fewer genes were associated with
abnormal (low) FMD, and only one gene was up- and one
gene was downregulated in patients with abnormal (high)
PWV. Differentially expressed genes primarily included
MHC-related genes, but also genes encoding cytokine,
adhesion molecule, integrin, and interferon-related ones.
Fig. 3 Study 2. Differential gene expression associated with vascular responses to 12-month anti-TNF therapy. Among the 19 patients, 10 showed
FMD-20%, 9 demonstrated IMT-20%, 8 showed PWV-20%, and 8 exerted GVR-20% responses. Heatmaps indicate differential gene regulation in
FMD-20% (a), IMT-20% (b), PWV-20% (c), and GVR-20% (d) responders (blue) vs non-responders (red). See Table S2 for the actual gene data
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In study 2, we treated 19 RA patients with TNF inhibi-
tors (either ETN or CZP) for 1 year. In the end, 13 pa-
tients showed a clinical response to treatment. We
defined vascular responses as at least 20% improvement
in FMD, IMT, and PWV after 12 months of biologic
treatment. We also defined GVR as ≥ 20% improvement
in at least two vascular parameters. Only 10–13 out of
19 patients had concordance between clinical and any
vascular response. Clinical response was associated with
the upregulation of five genes only. Again, some genes
were differentially expressed in IMT responder RA pa-
tients compared to non-responders. Very few genes were
associated with FMD, PWV, or GVR responses to
anti-TNF therapy. Here, differentially expressed genes
primarily included immunoglobulin- and HLA-related
genes, but also other genes including cytokine, chemo-
kine, and interferon-related genes.
A few particular genes were picked up in multiple ana-
lyses. Just to present a few interesting examples, two
vanin genes (VNN1 and VNN2) showed differential ex-
pression in study 1. Several interferon-related genes
(e.g., IFI44, IFIT1, IFITM3, IRF5) exerted differential ex-
pression in both studies. In SNP studies, IRF5 genetic
variants were associated with CV disease in RA [38]. Al-
though the role of vanins in RA is unknown, these mole-
cules have been implicated in fibrosis and vascular
pathology underlying other autoimmune conditions [39]
and atherosclerosis [40]. The gene for neurofilament
light polypeptide (NEFL) was significantly associated
with FMD, IMT, PWV, and GVR responses in study 2.
Neurofilament proteins have been associated with ner-
vous system damage in SLE [41]. However, cytoskeletal
neurofilaments have also been detected in the RA syno-
vium [42]. Antibodies to neurofilament proteins may
play a role in RA, as well as SLE [43]. Leucine-rich re-
peat neuronal 3 (LRRN3) gene exerted differential ex-
pression in RA patients with abnormal IMT and PWV in
study 1. This gene has been associated with aging [44].
Fig. 4 Pie chart shows the IMT-associated, overrepresented functional categories of the ClueGO pathway analysis (** p < 0.001,* p < 0.01, without
star p < 0.05)
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In general, leucine-rich repeat kinases (LRRK) are in-
volved in neuroinflammation, but also RA and other ar-
thritides [45]. Finally, in study 2, JUN, the gene encoding
the jun proto-oncogene, also showed differential expres-
sion in association with FMD-20% and PWV-20% re-
sponses. This molecule [46, 47], as well as c-Jun
N-terminal kinase (JNK) [48, 49], has long been associ-
ated with the pathogenesis of RA and atherosclerosis.
Certainly, several other genes and their roles in RA and/
or CV disease could have been demonstrated.
Conclusion
In order to demonstrate the function of the genes show-
ing differential expression in association with RA-related
vascular pathophysiology, GO analysis was performed
on IMT-associated, overrepresented genes. In general,
the differential expression of numerous genes was asso-
ciated with FMD, IMT, and PWV in RA. Genetic signa-
tures were also associated with clinical and vascular
responses to anti-TNF therapy. The major strength of
this study is that after SNP studies, this may be the first
one studying more complex genetic signatures in rela-
tion to RA-associated atherosclerosis. Our study may
have limitations including the relatively low number of
patients and that multiple testing could not be carried
out, so this study may lack power. Therefore, after this
pilot study, further, larger ones need to be conducted in
order to further delineate the genetic/genomic back-
ground of RA-related vascular disease.
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